Cariprazine is a new atypical antipsychotic drug (APD) with a unique pharmacodynamic
profile, different from both typical and atypical APDs. Specifically, cariprazine acts as a …

Although the development of second-generation antipsychotics was a cornerstone in the
treatment of schizophrenia, several unmet treatment needs in the field still exist. It is …

Schizophrenia is characterized by positive, negative, cognitive, and affective symptoms.
Antipsychotic medications, which work by blocking the dopamine D 2 receptor, are the …

Cariprazine is a novel drug with partial agonist activity at dopamine D2/3 receptors and six-
to eightfold higher affinity for human dopamine D3 over D2 receptors. Results from several …

IntroductionAll clinically effective antipsychotics are known to act on the dopaminergic
system, and previous studies have demonstrated that repeated treatment with antipsychotics …

Cariprazine (Vraylar™) is a dopamine D 3-preferring D 2/D 3 receptor partial agonist
indicated for the treatment of patients with schizophrenia. This narrative review summarizes …

Negative symptoms and cognitive impairment associated with schizophrenia are strongly
associated with poor functional outcome and reduced quality of life and remain an unmet …

Introduction Comorbidity of substance use disorder (SUD) with schizophrenia, referred to as
dual disorder (DD), significantly increases morbidity and mortality compared to …

Cariprazine (RGH-188, MP-214, Vraylar [TM]) is a new dopamine receptor ligand developed
for the treatment of several neuropsychiatric diseases including schizophrenia and bipolar …

Cariprazine is an antipsychotic medication and received approval by the US Food and Drug
Administration for the treatment of schizophrenia in September 2015. Cariprazine is a …